Boehringer In­gel­heim adds sec­ond AI part­ner in a month

Three weeks af­ter sign­ing a deal with one AI-fo­cused biotech, Boehringer In­gel­heim is adding an­oth­er.

The Ger­man phar­ma has an­nounced a part­ner­ship with BERG, the da­ta analy­sis and Bayesian AI com­pa­ny found­ed over a decade ago by re­al es­tate bil­lion­aire Carl Berg. Berg will use its com­put­er and wet lab plat­form to in­ves­ti­gate in­flam­ma­to­ry dis­eases, most no­tably at­tempt­ing com­ing up with caus­es, bio­mark­ers, drug tar­gets and drugs for in­flam­ma­to­ry bow­el dis­ease and Crohn’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER